Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302933 | 0.86 | MMP12 (0.65) | DRD4AHRMMP12PARP1KMT2A | |
| SCHEMBL30015279 | 0.86 | MMP12 (0.65) | DRD4AHRMMP12PARP1KMT2A | |
| SCHEMBL5987554 | 0.84 | MMP12 (0.63) | DRD4AHRMMP12PARP1KMT2A | |
| SCHEMBL6172784 | 0.79 | PPOX (0.50) | DRD4DRD2DRD3HTR1ACHRM5 | |
| SCHEMBL1861248 | 0.79 | NR3C2 (0.57) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL276741 | 0.79 | MMP12 (0.51) | DRD4DRD2DRD3HTR1ACHRM5 | |
| SCHEMBL30053776 | 0.79 | NR3C2 (0.57) | MMP12CYP11B1CYP11B2PARP1KIF11 | |
| SCHEMBL29512901 | 0.79 | MMP12 (0.51) | DRD4DRD2DRD3HTR1ACHRM5 | |
| SCHEMBL3594625 | 0.79 | MMP12 (0.51) | DRD4DRD2DRD3HTR1ACHRM5 | |
| SCHEMBL30336661 | 0.79 | MMP12 (0.51) | DRD4DRD2DRD3HTR1ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63295567-A | — | — | None | — | — | JP | disclosed |
| EP-3160948-B1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| US-10017502-B2 | Benzoxazinone amides as mineralocorticoid receptor modulators | ASTRAZENECA AB (SE) | 2018-07-10 | — | — | US | disclosed |
| US-20170217945-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-03 | — | — | US | disclosed |
| EP-3160948-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2017-05-03 | — | — | EP | disclosed |
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9394291-B2 | Benzoxazinone amides as mineralocorticoid receptor modulators | ASTRAZENECA AB (SE) | 2016-07-19 | — | — | US | disclosed |
| WO-2016001631-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2016-01-07 | — | — | WO | disclosed |
| US-20150376170-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2015-12-31 | — | — | US | disclosed |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20060199810-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| JP-S63295567-A | PROCESS FOR PRODUCTION OF 3,4-DIHYDRO-2H-1,4-BENZOXAZINE WITH INDUSTRIAL ADVANTAGE | KYORIN PHARMACEUT CO LTD | 1988-12-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | DRD4 1302/4885DRD2 599/4885DRD3 1008/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | DRD4 266/4885DRD2 166/4885DRD3 269/4885 |
| US-20170217945-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | NR3C2, CYP11B1, CYP11B2 | DRD4 2329/4885DRD2 2294/4885DRD3 2432/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | DRD4 1302/4885DRD2 599/4885DRD3 1008/4885 |
| US-10017502-B2 | Benzoxazinone amides as mineralocorticoid receptor modulators | NR3C2, CYP11B1, CYP11B2 | DRD4 2329/4885DRD2 2294/4885DRD3 2432/4885 |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | DRD4 1302/4885DRD2 599/4885DRD3 1008/4885 |
| US-20060199810-A1 | Muscarinic agonists | CHRM3, CHRM5, CHRM2 | DRD4 1280/4885DRD2 623/4885DRD3 977/4885 |
| US-20150376170-A1 | BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS | NR3C2, CYP11B2, CYP11B1 | DRD4 2443/4885DRD2 2479/4885DRD3 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.